STARLIGHT THERAPEUTICS

Serial Number 97790983
688

Registration Progress

Application Filed
Feb 11, 2023
Under Examination
Jun 3, 2025
Approved for Publication
Apr 8, 2025
Published for Opposition
Apr 8, 2025
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Dec 03, 2025 138 days

Trademark Image

STARLIGHT THERAPEUTICS

Basic Information

Serial Number
97790983
Filing Date
February 11, 2023
Published for Opposition
April 8, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
688
Status Date
Jun 3, 2025
Application
Pending
Classes
042

Rights Holder

STARLIGHT THERAPEUTICS INC.

03
Address
1920 McKinney Avenue, 7th Floor
Dallas, TX 75201

Ownership History

STARLIGHT THERAPEUTICS INC.

Original Applicant
03
Dallas, TX

STARLIGHT THERAPEUTICS INC.

Owner at Publication
03
Dallas, TX

Legal Representation

Attorney
NIGAMNARAYAN ACHARYA

USPTO Deadlines

Next Deadline
138 days remaining
NOA E-Mailed - SOU Required
Due Date
December 03, 2025
Extension Available
Until June 03, 2026

Application History

30 events
Date Code Type Description Documents
Jun 3, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Apr 8, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 8, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 2, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 13, 2025 EXPT T EXPARTE APPEAL TERMINATED Loading...
Mar 13, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 11, 2025 EXPI T EX PARTE APPEAL-INSTITUTED Loading...
Feb 11, 2025 JURT T JURISDICTION RESTORED TO EXAMINING ATTORNEY Loading...
Feb 6, 2025 PGTT O PETITION GRANTED - TTAB APPEAL FILED Loading...
Feb 6, 2025 NREV E NOTICE OF REVIVAL - E-MAILED Loading...
Feb 4, 2025 APET A ASSIGNED TO PETITION STAFF Loading...
Jan 18, 2025 EXAF T EXPARTE APPEAL RECEIVED AT TTAB Loading...
Dec 17, 2024 EXAF T EXPARTE APPEAL RECEIVED AT TTAB Loading...
Dec 17, 2024 PROA I TEAS PETITION TO REVIVE RECEIVED Loading...
Oct 17, 2024 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Oct 17, 2024 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
Jul 3, 2024 CNFR R FINAL REFUSAL WRITTEN Loading...
Jul 3, 2024 GNFR O FINAL REFUSAL E-MAILED Loading...
Jul 3, 2024 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
May 14, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
May 14, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 14, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 14, 2024 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Feb 14, 2024 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Nov 14, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Nov 14, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Nov 14, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Nov 9, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 2, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 15, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Pharmaceutical research and development services in the field of oncology, namely, neuro and central nervous system oncology; pharmaceutical drug discovery services in the field of oncology; scientific and medical research and development for pharmaceuticals, pharmaceutical preparations and substances in the field of oncology, namely, neuro and central nervous system oncology

Classification

International Classes
042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
THERAPEUTICS